BUREN served as local counsel to SAI MedPartners (SAI), a global consultancy specialising in strategic insights and analytics for the pharmaceutical, biotechnology, and medical device sectors, in its acquisition of IDEA Pharma (IDEA). Northlane Capital Partners had acquired SAI in June 2022.
SAI, headquartered in Pennsylvania, USA, offers competitive intelligence and strategy support throughout the product lifecycle to pharmaceutical, biotechnology, and medical device firms globally. IDEA, based in London, specialises in pharmaceutical path-to-market strategy and innovation and has employees across Europe and the United States. This acquisition combines IDEA’s expertise in early-phase positioning, clinical development, and commercialisation with SAI’s strengths in competitive intelligence, market research, and market access consulting to deliver unique solutions for biopharma clients.